# Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age

> **NCT05193279** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Clover Biopharmaceuticals AUS Pty**

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Candidate vaccine, SCB-2019

## Key facts

- **NCT ID:** NCT05193279
- **Lead sponsor:** Clover Biopharmaceuticals AUS Pty
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-10-05
- **Primary completion:** 2022-12-15
- **Final completion:** 2022-12-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was terminated during the EC submission process prior to the enrollment.
- **Last updated:** 2023-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05193279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05193279, "Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT05193279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*